N/A
N=1,523
A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)
Type 2 Diabetes Mellitus
Bottom Line
View on ClinicalTrials.gov: NCT01409213 ↗Enrolled (actual)
1,523
Serious AEs
—
Results posted
Jan 2012
Primary outcome: Primary: Change From Baseline for Mean Hemoglobin A1c (HbA1C) — 6.9; -0.5 Percent of glycosylated hemoglobin
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Merck Sharp & Dohme LLC
- Primary completion
- Jan 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline for Mean Hemoglobin A1c (HbA1C) |
6.9; -0.5 | — |
| PRIMARY Change From Baseline for Mean Fasting Blood Glucose (FBG) |
127.8; -18.6 | — |
Summary
The purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabetic patients type 2 published by the Deutsche Diabetes Gesellschaft (DDG) on October 13, 2008
Eligibility Criteria
Inclusion Criteria
- Newly diagnosed with Type 2 diabetes in whom treatment with metformin in
the individual maximal tolerated dose (at least four weeks on stable dose) resulted in
HbA1c >6.5%
- No contraindication or intolerability to metformin
Exclusion Criteria
- Currently being administered a combination therapy for the treatment of their Type 2 diabetes
Data sourced from ClinicalTrials.gov (NCT01409213). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.